Celldex Therapeutics Inc (NASDAQ: CLDX) kicked off on Monday, down -4.33% from the previous trading day, before settling in for the closing price of $21.26. Over the past 52 weeks, CLDX has traded in a range of $14.40-$47.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 14.46%. While this was happening, its average annual earnings per share was recorded -40.83%. With a float of $64.51 million, this company’s outstanding shares have now reached $66.38 million.
Let’s determine the extent of company efficiency that accounts for 186 employees. In terms of profitability, gross margin is 78.62%, operating margin of -2873.52%, and the pretax margin is -2366.07%.
Celldex Therapeutics Inc (CLDX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Celldex Therapeutics Inc is 2.84%, while institutional ownership is 109.39%. The most recent insider transaction that took place on Nov 11 ’24, was worth 308,430. In this transaction PRESIDENT & CEO of this company bought 11,500 shares at a rate of $26.82, taking the stock ownership to the 40,284 shares.
Celldex Therapeutics Inc (CLDX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -40.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -16.47% during the next five years compared to 6.91% growth over the previous five years of trading.
Celldex Therapeutics Inc (NASDAQ: CLDX) Trading Performance Indicators
Take a look at Celldex Therapeutics Inc’s (CLDX) current performance indicators. Last quarter, stock had a quick ratio of 21.67. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 178.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.70, a number that is poised to hit -0.86 in the next quarter and is forecasted to reach -4.02 in one year’s time.
Technical Analysis of Celldex Therapeutics Inc (CLDX)
Looking closely at Celldex Therapeutics Inc (NASDAQ: CLDX), its last 5-days average volume was 1.64 million, which is a jump from its year-to-date volume of 0.92 million. As of the previous 9 days, the stock’s Stochastic %D was 35.91%. Additionally, its Average True Range was 1.43.
During the past 100 days, Celldex Therapeutics Inc’s (CLDX) raw stochastic average was set at 50.08%, which indicates a significant increase from 32.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.20% in the past 14 days, which was higher than the 60.43% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.38, while its 200-day Moving Average is $25.15. However, in the short run, Celldex Therapeutics Inc’s stock first resistance to watch stands at $21.22. Second resistance stands at $22.11. The third major resistance level sits at $22.78. If the price goes on to break the first support level at $19.66, it is likely to go to the next support level at $18.99. Now, if the price goes above the second support level, the third support stands at $18.10.
Celldex Therapeutics Inc (NASDAQ: CLDX) Key Stats
The company with the Market Capitalisation of 1.35 billion has total of 66,384K Shares Outstanding. Its annual sales at the moment are 7,020 K in contrast with the sum of -157,860 K annual income. Company’s last quarter sales were recorded 700 K and last quarter income was -53,800 K.
